Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

909
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
909
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

23
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
23
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

77
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
77
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CRT-Estimands Framework: consensus based extension of the ICH E9(R1) addendum for cluster randomised trials.

BMJ (Clinical research ed.)·2026
Same author

Additional crossovers in cluster randomised crossover trials do not always increase statistical power.

Clinical trials (London, England)·2026
Same author

Comparing meta-analysis and linear mixed model-based approaches for the analysis of continuous outcomes from batched stepped wedge trials.

Clinical trials (London, England)·2026
Same author

Moderating role of CEO expertise on the relationship between capital structure and financial reporting timeliness of Saudi-listed companies.

PloS one·2026
Same author

Repeated inclusion cluster randomized trials: a new class of designs for assessing group-level interventions.

Biometrics·2026
Same author

Activated ATF6α is a hepatic tumour driver restricting immunosurveillance.

Nature·2026
Same journal

Variation in Emergency Department Experience With Pediatric Critical Illness.

Annals of emergency medicine·2026
Same journal

Point-of-Care Ultrasound-Guided Hydrostatic Reduction of Ileocolic Intussusception in the Pediatric Emergency Department.

Annals of emergency medicine·2026
Same journal

Managing Diabetic Ketoacidosis.

Annals of emergency medicine·2026
Same journal

Needle Thoracostomy: Implications of Chest Wall Thickness for Anatomical Location and Needle Length.

Annals of emergency medicine·2026
Same journal

Women Emergency Physicians and Gender Disparities from Entry to Advancement.

Annals of emergency medicine·2026
Same journal

Policy Statements Approved March 2026.

Annals of emergency medicine·2026
See all related articles

Related Experiment Video

Updated: Sep 13, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Tranexamic Acid Timing and Mortality Impact After Trauma.

Adnan Ali1, Russell L Gruen2, Stephen A Bernard3

  • 1Clinical Hub for Interventional Research, John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia.

Annals of Emergency Medicine
|August 2, 2025
PubMed
Summary
This summary is machine-generated.

Early administration of tranexamic acid (TXA) within 90 minutes of injury significantly reduces trauma mortality. Beyond this window, TXA shows no significant benefit in preventing 28-day deaths in trauma patients.

Keywords:
InjuryRandomized controlled trialTranexamic acidTrauma

More Related Videos

A Saline/Bipolar Radiofrequency Energy Device As an Adjunct for Hemostasis in Solid Organ Injury/Trauma
04:20

A Saline/Bipolar Radiofrequency Energy Device As an Adjunct for Hemostasis in Solid Organ Injury/Trauma

Published on: July 28, 2020

5.3K
Integrated Compensatory Responses in a Human Model of Hemorrhage
07:57

Integrated Compensatory Responses in a Human Model of Hemorrhage

Published on: November 20, 2016

12.6K

Related Experiment Videos

Last Updated: Sep 13, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K
A Saline/Bipolar Radiofrequency Energy Device As an Adjunct for Hemostasis in Solid Organ Injury/Trauma
04:20

A Saline/Bipolar Radiofrequency Energy Device As an Adjunct for Hemostasis in Solid Organ Injury/Trauma

Published on: July 28, 2020

5.3K
Integrated Compensatory Responses in a Human Model of Hemorrhage
07:57

Integrated Compensatory Responses in a Human Model of Hemorrhage

Published on: November 20, 2016

12.6K

Area of Science:

  • Trauma resuscitation
  • Emergency medicine
  • Pharmacology

Background:

  • Current trauma resuscitation guidelines recommend tranexamic acid (TXA) within 3 hours of injury, based on CRASH-2 trial data.
  • This 3-hour window has not been independently replicated, prompting further investigation into optimal timing.

Purpose of the Study:

  • To determine if 28-day mortality after trauma varies with the time to the first TXA dose.
  • To precisely define the therapeutic window for TXA administration in major trauma patients.

Main Methods:

  • Exploratory analysis of the PATCH-Trauma trial involving adults with major trauma and suspected coagulopathy.
  • Patients received either TXA or placebo; time from injury to first TXA dose was analyzed using continuous functions.
  • Log-binomial regression was used to assess mortality risk within 28 days based on treatment timing.

Main Results:

  • The study included 1,287 patients; median time to first TXA dose was 79 minutes.
  • Mortality risk increased with delayed TXA administration, with benefits most pronounced up to 90 minutes post-injury.
  • TXA administration within 90 minutes significantly reduced 28-day mortality (aRR 0.64), while administration after 90 minutes showed no significant benefit (aRR 1.04).

Conclusions:

  • The optimal therapeutic window for administering TXA in trauma patients appears to be within 90 minutes of injury.
  • This finding suggests a narrower, more critical window for TXA efficacy than previously established.